The second quarter of 2025 picked up where the first quarter left off with a somewhat muted novel drug approval landscape. Q1’s total of seven novel drug approvals was low by recent standards and Q2’s nine approvals are not a step change. Moreover, commercial expectations for the Q2 cohort are lower, based on Evaluate Pharma forecasts for sales in 2030 (Table 1).
Enjoying our latest content?
Log in or create an account to continue
- Access the most recent journalism from Nature's award-winning team
- Explore the latest features & opinion covering groundbreaking research
or
Competing Interests
The author declares no competing interests.
